1324-OR: A β-klotho Antibody Conjugated to GLP-1/GCG/GIP Triple Agonist Demonstrates Robust Body Weight Reduction and Metabolic Improvement in Obese Rodents and Nonhuman Primates

Introduction and Objective: Obesity is a major driver of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), conditions with substantial unmet medical need. This study aimed to characterize XWDAPC-1, a novel long-acting β-klotho antibody-GLP-1/GCG/GIP quadragonist, for its metabolic efficacy and pharmacological profile. Methods: The in vitro activity of XWDAPC-1 was evaluated using cell-based assays expressing β-klotho, GLP-1 receptor (GLP-1R), glucagon receptor (GCGR), or glucose-dependent insulinotropic polypeptide receptor (GIPR). In vivo efficacy was assessed in diet-induced obese (DIO) mice and obese male cynomolgus monkeys. Pharmacokinetic (PK) properties were evaluated in male cynomolgus monkeys. Results: XWDAPC-1 exhibited robust agonist activity across β-klotho, GLP-1R, GCGR, and GIPR assays. In DIO mice, a single dose of XWDAPC-1 induced sustained and greater body weight reduction compared with MariTide. In obese cynomolgus monkeys, XWDAPC-1 consistently produced substantial body weight control and modulation of plasma metabolic biomarkers. PK analysis in cynomolgus monkeys demonstrated profiles comparable to MariTide, supporting monthly dosing interval. Conclusion: XWDAPC-1 demonstrates strong in vitro potency, robust in vivo metabolic efficacy, and favorable pharmacokinetic properties. These findings support XWDAPC-1 as a promising therapeutic candidate for the treatment of obesity and related metabolic liver diseases, including MASLD and MASH. Disclosure H. Zou: Employee; Current; Sciwind Biosciences. Y. Wang: Employee; Current; Sciwind Biosciences. R. Zhu: Employee; Current; Sciwind Biosciences. J. Zhao: Employee; Current; Sciwind Biosciences. D. Jia: Employee; Current; Sciwind Biosciences. J. Deng: Employee; Current; Sciwind Biosciences. X. Wu: Employee; Current; Sciwind Biosciences.

Authors

Publication Details

Journal
Diabetes
Published
2026-06-08
DOI
https://doi.org/10.2337/db26-1324-or
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

1324-OR: A β-klotho Antibody Conjugated to GLP-1/GCG/GIP Triple Agonist Demonstrates Robust Body Weight Reduction and Metabolic Improvement in Obese Rodents and Nonhuman Primates

Haixia Zou, JIANHUI DENG, JINYI ZHAO, Yan Wang et al.
Diabetes
Diabetes Treatment and Management
article

1324-OR: A β-klotho Antibody Conjugated to GLP-1/GCG/GIP Triple Agonist Demonstrates Robust Body Weight Reduction and Metabolic Improvement in Obese Rodents and Nonhuman Primates

Haixia Zou, JIANHUI DENG, JINYI ZHAO, Yan Wang, DAN JIA, XINLE WU, Rui Zhu
article en

Abstract

Introduction and Objective: Obesity is a major driver of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), conditions with substantial unmet medical need. This study aimed to characterize XWDAPC-1, a novel long-acting β-klotho antibody-GLP-1/GCG/GIP quadragonist, for its metabolic efficacy and pharmacological profile. Methods: The in vitro activity of XWDAPC-1 was evaluated using cell-based assays expressing β-klotho, GLP-1 receptor (GLP-1R), glucagon receptor (GCGR), or glucose-dependent insulinotropic polypeptide receptor (GIPR). In vivo efficacy was assessed in diet-induced obese (DIO) mice and obese male cynomolgus monkeys. Pharmacokinetic (PK) properties were evaluated in male cynomolgus monkeys. Results: XWDAPC-1 exhibited robust agonist activity across β-klotho, GLP-1R, GCGR, and GIPR assays. In DIO mice, a single dose of XWDAPC-1 induced sustained and greater body weight reduction compared with MariTide. In obese cynomolgus monkeys, XWDAPC-1 consistently produced substantial body weight control and modulation of plasma metabolic biomarkers. PK analysis in cynomolgus monkeys demonstrated profiles comparable to MariTide, supporting monthly dosing interval. Conclusion: XWDAPC-1 demonstrates strong in vitro potency, robust in vivo metabolic efficacy, and favorable pharmacokinetic properties. These findings support XWDAPC-1 as a promising therapeutic candidate for the treatment of obesity and related metabolic liver diseases, including MASLD and MASH. Disclosure H. Zou: Employee; Current; Sciwind Biosciences. Y. Wang: Employee; Current; Sciwind Biosciences. R. Zhu: Employee; Current; Sciwind Biosciences. J. Zhao: Employee; Current; Sciwind Biosciences. D. Jia: Employee; Current; Sciwind Biosciences. J. Deng: Employee; Current; Sciwind Biosciences. X. Wu: Employee; Current; Sciwind Biosciences.

DiabetesVol. 75(Supplement_1)
Openalex Percentile: Top 7%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.